Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network-Reference-Cited by-同舟云学术

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network

Published:2020-10-12 Issue:2 Volume:30 Page:229-236
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Ruigómez Ana¹^ORCID,Brobert Gunnar²^ORCID,Vora Pareen³^ORCID,García Rodríguez Luis A.¹^ORCID

Affiliation:

1. Spanish Centre for Pharmacoepidemiologic Research (CEIFE) Madrid Spain

2. Bayer AB Stockholm Sweden

3. Bayer AG Berlin Germany

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5146

Reference28 articles.

1. European Medicines Agency.Xarelto. Summary of Product Characteristics.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000944/WC500057108.pdf. Accessed 14 July 2020.

2. The changing face of venous thromboembolism management in England

3. Oral Rivaroxaban for Symptomatic Venous Thromboembolism

4. Rivaroxaban and the EINSTEIN clinical trial programme

5. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries;PLOS ONE;2024-03-07

2. Venous Thromboembolism Among People With HIV: Design, Implementation, and Findings of a Centralized Adjudication System in Clinical Care Sites Across the United States;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-02-01

3. Validity of Routine Health Data To Identify Safety Outcomes of Interest For Covid-19 Vaccines and Therapeutics in the Context of the Emerging Pandemic: A Comprehensive Literature Review;Drug, Healthcare and Patient Safety;2024-01

4. Safety profile of rivaroxaban in first-time users treated for venous thromboembolism (deep vein thrombosis and pulmonary embolism) in four European countries;2023-04-17

5. Association between glycemic control and risk of venous thromboembolism in diabetic patients: a nested case–control study;Cardiovascular Diabetology;2022-01-04